NCT04318899 Predictors of Clinical Course and Treatment Response in DBT Programmes
| NCT ID | NCT04318899 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Self Harm |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2018-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2018-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The project is a collaboration between The National Centre for Suicide Research and Prevention (NSSF) and clinical units with Dialectical Behaviour Therapy (DBT) programmes. A methodological and technological platform has been established that enables clinicians to deliver high quality treatments over extended periods of time, to evaluate their own performance and productivity and to report it in a uniform and systematic way that will enable comparison across clinical settings and programmes. The collected data constitute the basis for conducting the clinical study with the overall aim to study predictors of the clinical course and treatment response in patients admitted to DBT programmes in Norway.
Eligibility Criteria
Inclusion Criteria: * History of repeated deliberate self harm * Satisfies criteria of Diagnostic and Statistical Manual (DSM-IV) Borderline Personality Disorder as measured by Structured Clinical Interview for the DSM (SCID-II) in addition to the self-destructive criterion. Exclusion Criteria: * Psychotic disorders * Anorexia Nervosa * Substance dependence disorder * Mental retardation (IQ less than 70) * Asperger syndrome/autism
Contact & Investigator
Lars Mehlum, MD PhD
PRINCIPAL INVESTIGATOR
University of Oslo
Frequently Asked Questions
Who can join the NCT04318899 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 70 Years, studying Self Harm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04318899 currently recruiting?
Yes, NCT04318899 is actively recruiting participants. Contact the research team at egil.haga@medisin.uio.no for enrollment information.
Where is the NCT04318899 trial being conducted?
This trial is being conducted at Oslo, Norway, Moss, Norway, Sandnessjøen, Norway, Sandvika, Norway and 1 additional location.
Who is sponsoring the NCT04318899 clinical trial?
NCT04318899 is sponsored by Oslo University Hospital. The principal investigator is Lars Mehlum, MD PhD at University of Oslo. The trial plans to enroll 250 participants.